A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Syndrome
Latest Information Update: 22 May 2025
At a glance
- Drugs Osilodrostat (Primary)
- Indications Cushing syndrome
- Focus Pharmacokinetics
- Sponsors Recordati; Recordati Industria Chimica & Farmaceutica SPA
Most Recent Events
- 21 May 2024 Planned End Date changed from 29 Nov 2023 to 21 Nov 2025.
- 21 May 2024 Planned primary completion date changed from 21 Feb 2023 to 21 Nov 2025.
- 07 May 2024 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified May 2022).